https://www.selleckchem.com/pr....oducts/Everolimus(RA
Interestingly 2 and 3 are thermally stable and they do not undergo benzyne formation via LiF elimination. Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal outcomes and the effect of empagliflozin in patients with MetS enrolled in the EMPA-REG OUTCOME trial. A total of 7020 patients with T2D and atherosclerotic cardiovascular disease were treated with empagliflozin (10mg
Like
Comment
Share
